Fig. 2From: Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusa Immunohistochemistry for MLH1 protein on the primary tumour showing a heterogeneous expression profile. b Microsatellite testing results according to different areas of the primary tumour. c MLH1 proficiency documented in baseline diagnostic biopsy. d MLH1 loss documented in synchronous peritoneal metastasis. Scale bar indicates 100 μmBack to article page